Trial Profile
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Enzalutamide (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Feb 2024 Planned End Date changed from 31 Dec 2023 to 1 Jul 2024.
- 21 Jul 2023 Planned End Date changed from 31 Aug 2025 to 31 Dec 2023.
- 06 Jun 2023 Results from final analysis of ORR, rPFS and OS, presented at the 59th Annual Meeting of the American Society of Clinical Oncology